Dominari (DOMH) 10-Q 9 May 24 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2024	May 07, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Entity Information [Line Items]
Entity Registrant Name	DOMINARI HOLDINGS INC.
Entity Central Index Key	0000012239
Entity File Number	001-41845
Entity Tax Identification Number	52-0849320
Entity Incorporation, State or Country Code	DE
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	725 5th Avenue
Entity Address, Address Line Two	22nd Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10022
Entity Phone Fax Numbers [Line Items]
City Area Code	(212)
Local Phone Number	393-4540
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock ($0.0001 par value per share)
Trading Symbol	DOMH
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		5,934,917

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 1,956	$ 2,833
Marketable securities	5,123	13,547
Deposits with clearing broker	14,094	7,687
Prepaid expenses and other assets	2,230	898
Notes receivable, at fair value - current portion	1,955	3,177
Total current assets	25,358	28,142
Property and equipment, net	317	344
Notes receivable, at fair value - non-current portion	1,128	1,129
Long-term equity investments	21,691	24,150
Right-of-use assets	3,242	3,335
Security deposit	458	458
Total assets	52,194	57,558
Current liabilities
Accounts payable and accrued expenses	840	1,036
Accrued salaries and benefits		51
Accrued commissions	295	77
Lease liability - current	419	421
Other current liability	42	22
Total current liabilities	1,596	1,607
Lease liability, less current portion	2,929	3,028
Total liabilities	4,525	4,635
Stockholders’ equity
Preferred stock value
Common stock, $0.0001 par value, 100,000,000 shares authorized; 5,995,065 shares issued as of March 31, 2024 and December 31, 2023; 5,934,917 shares outstanding as of March 31, 2024 and December 31, 2023
Additional paid-in capital	262,374	262,187
Treasury stock, as of cost, 60,148 shares as of March 31, 2024 and December 31, 2023	(501)	(501)
Accumulated deficit	(214,204)	(208,763)
Total stockholders’ equity	47,669	52,923
Total liabilities and stockholders’ equity	52,194	57,558
Series D Preferred Stock
Stockholders’ equity
Preferred stock value
Series D-1 Preferred Stock
Stockholders’ equity
Preferred stock value

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	50,000,000	50,000,000
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	5,995,065	5,995,065
Common stock, shares outstanding	5,934,917	5,934,917
Treasury stock, at cost	60,148	60,148
Series D Preferred Stock
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	3,825	3,825
Preferred stock, shares outstanding	3,825	3,825
Liquidation preference (in Dollars per share)	$ 0.0001	$ 0.0001
Series D-1 Preferred Stock
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	834	834
Preferred stock, shares outstanding	834	834
Liquidation preference (in Dollars per share)	$ 0.0001	$ 0.0001

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 1,367
Operating costs and expenses
General and administrative	4,172	3,834
Total operating expenses	4,172	3,834
Loss from operations	(2,805)	(3,834)
Other income (expenses)
Interest income	164	137
Gain (loss) on marketable securities, net	574	(65)
Realized and unrealized gain and loss on notes receivable, net	(915)
Change in fair value of long-term equity investments	(2,459)
Total other income (expenses)	(2,636)	72
Net loss	$ (5,441)	$ (3,762)
Net loss per share, basic and diluted
Basic (in Dollars per share)	$ (0.91)	$ (0.71)
Weighted average number of shares outstanding, basic and diluted
Basic (in Shares)	5,995,065	5,305,513

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Diluted	$ (0.91)	$ (0.71)
Diluted	5,995,065	5,305,513

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Deficit	Total
Balance at Dec. 31, 2022			$ 262,970	$ (3,322)	$ (185,881)	$ 73,767
Balance (in Shares) at Dec. 31, 2022	4,659	5,485,096		468,017
Stock-based compensation			5			5
Cancellation of common stock
Cancellation of common stock (in Shares)		(25,000)
Purchase of treasury stock				$ (939)		(939)
Purchase of treasury stock (in Shares)				236,630
Retirement of treasury stock			(3,760)	$ 3,760
Retirement of treasury stock (in Shares)		(644,499)		(644,499)
Net loss					(3,762)	(3,762)
Balance at Mar. 31, 2023			259,215	$ (501)	(189,643)	69,071
Balance (in Shares) at Mar. 31, 2023	4,659	4,815,597		60,148
Balance at Dec. 31, 2023			262,187	$ (501)	(208,763)	52,923
Balance (in Shares) at Dec. 31, 2023	4,659	5,995,065		60,148
Stock-based compensation			187			187
Net loss					(5,441)	(5,441)
Balance at Mar. 31, 2024			$ 262,374	$ (501)	$ (214,204)	$ 47,669
Balance (in Shares) at Mar. 31, 2024	4,659	5,995,065		60,148

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities
Net loss	$ (5,441)	$ (3,762)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of right-of-use assets	93	92
Depreciation	26	7
Change in fair value of long-term equity investments	2,459
Stock-based compensation	187	5
Realized loss on marketable securities	93	56
Unrealized (gain) loss on marketable securities	(473)	130
Realized and unrealized gain and loss on notes receivable, net	915
Changes in operating assets and liabilities:
Prepaid expenses and other assets	6	(221)
Prepaid acquisition cost		301
Clearing broker deposits	(6,407)
Accounts payable and accrued expenses	(196)	(19)
Accrued salaries and benefits	(51)	(528)
Accrued commissions	218
Lease liabilities	(101)	7
Other current liabilities	20	3
Notes receivable, at fair value – net interest accrued	58	(62)
Net cash used in operating activities	(8,594)	(3,991)
Cash flows from investing activities
Purchase of marketable securities	(24)	(17,519)
Sale of marketable securities	8,829	68
Purchase of fixed assets		(361)
Acquisition of FPS, net of cash acquired and receivable owed from FPS		(1,149)
Collection of principal on notes receivable	250	250
Loans to employees	(1,340)
Collection of loans to employees	2
Net cash provided by (used in) investing activities	7,717	(18,711)
Cash flows from financing activities
Purchase of treasury stock		(939)
Net cash used in financing activities		(939)
Net decrease in cash and cash equivalents and restricted cash	(877)	(23,641)
Cash and cash equivalents, beginning of period	2,833	33,174
Cash and cash equivalents, end of period	$ 1,956	$ 9,533

Organization and Description of

Organization and Description of Business and Recent Developments	3 Months Ended
	Mar. 31, 2024
Organization and Description of Business and Recent Developments [Abstract]
Organization and Description of Business and Recent Developments	Note 1. Organization and Description of Business and Recent Developments Organization and Description of Business Dominari Holdings Inc. (the “Company”), formerly AIkido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company has operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. The Company is in the process of winding down its historical pipeline of biotechnology assets held by Aikido Labs, LLC. In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (“Dominari Securities”), an introducing broker-dealer, registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”). Dominari Securities provides investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers. On September 9, 2022, Dominari Financial entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank & Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the SEC. Pursuant to the terms of the FPS Purchase Agreement, Dominari Financial purchased from the Seller 100% of the membership interests in FPS (the “Membership Interests”). FPS’s registered broker-dealer and investment adviser businesses will be operated as a wholly owned subsidiary of Dominari Financial. The FPS Purchase Agreement provides for Dominari Financial’s acquisition of FPS’s Membership Interests in two closings, the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari Financial paid to the Seller $2.0 million in consideration for a transfer by the Seller to Dominari Financial 20% of the FPS Membership Interests. Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”). The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing occurred on March 27, 2023. Dominari Financial paid to the Seller an additional $1.4 million in consideration for a transfer by the Seller to Dominari Financial of the remaining 80% of the Membership Interests. As a result of the ownership change, FPS was renamed Dominari Securities LLC.

Liquidity and Capital Resources

Liquidity and Capital Resources	3 Months Ended
	Mar. 31, 2024
Liquidity and Capital Resources [Abstract]
Liquidity and Capital Resources	Note 2. Liquidity and Capital Resources The Company continues to incur ongoing administrative and other expenses, including public company expenses, in excess of corresponding (non-financing related) revenue. While the Company continues to implement its business strategy, it intends to finance its activities through managing current cash on hand from the Company’s past equity offerings. Based upon projected cash flow requirements, the Company has adequate cash and cash equivalents and marketable securities to fund its operations for at least the next twelve months from the date of the issuance of these unaudited condensed consolidated financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3. Summary of Significant Accounting Policies There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the 2023 Annual Report. Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed consolidated balance sheet as of March 31, 2024, condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023, condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2024 and 2023, and the condensed consolidated statements of cash flows for the three months ended March 31, 2024 and 2023 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three months ended March 31, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024 or for any future interim period. The condensed consolidated balance sheet as of December 31, 2023 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2023. The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions. Deposits with clearing broker Deposits with Dominari Securities’ clearing broker consisted of approximately $14.1 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of March 31, 2024. Leases The Company accounts for its leases under ASC 842, Leases Leases Revenue The Company recognizes revenue under ASC 606 - Revenue from Contracts with Customers . The following provides detailed information on the recognition of the Company’s revenue from contracts with customers: ● Underwriting services include underwriting and placement agent services in both the equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenue are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the unaudited condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income. ● Commissions are earned by executing transactions for clients primarily in equity, equity-related, and debt products. Commission revenue associated with trade execution are recognized at a point in time on trade-date. Commissions revenue are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date. ● Account advisory fees are earned in connection with investment advisory services. Account advisory fees are recognized over time using the time elapsed method as the Company determined that the customer simultaneously receives and consumes the benefits of investment advisory services as they are provided. Account advisory fees are generally paid in advance of a specified service period (e.g. quarterly) and are initially deferred within in our Condensed Consolidated Balance Sheet. ● Other revenue includes placement agent services in the equity capital markets for privately held companies distributing private equity. Placement agent revenue are recognized at a point in time on trade-date, as the client obtains the control and benefit of the membership interest offering at that point. Long-term equity investments The Company accounts for long-term equity investments under Accounting Standards Codification (“ASC”) 321 “Investments—Equity Securities” (“ASC 321”). In accordance with ASC 321, equity securities with readily determinable fair values are accounted for at fair value based on quoted market prices. Equity securities without readily determinable fair values are accounted for either at fair value or using the measurement alternative. Under the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the Company. Recently adopted accounting standards In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions In March 2023, the FASB issued ASU 2023-01, Leases Effect of new accounting pronouncements to be adopted in future periods The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.

Marketable Securities

Marketable Securities	3 Months Ended
	Mar. 31, 2024
Marketable Securities [Abstract]
Marketable Securities	Note 4. Marketable Securities The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three months ended March 31, 2024 and 2023, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands): Three Months Ended 2024 2023 Realized loss $ (93 ) $ (56 ) Unrealized gain (loss) 473 (130 ) Dividend income 193 121 Total $ 574 $ (65 )

Long-Term Equity Investments

Long-Term Equity Investments	3 Months Ended
	Mar. 31, 2024
Long-Term Equity Investments [Abstract]
Long-Term Equity Investments	Note 5. Long-Term Equity Investments The Company holds interests in several privately held and publicly traded companies as long-term investments. The following table presents the Company’s long-term investments as of March 31, 2024, and December 31, 2023 ($ in thousands): Cost Basis March 31, December 31, Investment in Kerna Health Inc $ 2,140 $ 4,940 $ 4,940 Investment in Kaya Now 1,500 - - Investment in Tevva Motors 1,972 2,794 2,794 Investment in ASP Isotopes 1,300 - - Investment in Unusual Machines 1,075 813 1,033 Investment in Qxpress* 1,000 1,000 1,000 Investment in Masterclass* 170 170 170 Investment in Kraken* 597 597 597 Investment in Epic Games* 3,500 2,626 3,500 Investment in Tesspay** 1,240 2,981 2,679 Investment in SpaceX* 3,500 3,500 4,867 Investment in Databricks* 1,200 842 842 Investment in Discord* 476 476 476 Investment in Thrasio* 300 - 300 Investment in Automation Anywhere* 476 476 476 Investment in Anduril* 476 476 476 Total $ 20,922 $ 21,691 $ 24,150 * Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly. ** Investments made in these companies are through both an SPV and direct investments. Investment in SpaceX The Company redeemed its entire investment in the portfolio company during April 2024 in exchange for return of cost basis of $3.5 million. Investment in Unusual Machines Unusual Machines, Inc, an emerging leader in first-person view (FPV) drone technology, closed its initial public offering of common stock on February 14, 2024 at a public offering price of $4 per share and the shares began trading on the NYSE American under the ticker symbol “UMAC”. As of March 31, 2024 the Company valued its investment in Unusual Machines based on UMAC’s market price.

Notes Receivable

Notes Receivable	3 Months Ended
	Mar. 31, 2024
Notes Receivable [Abstract]
Notes Receivable	Note 6. Notes Receivable The following table presents the Company’s notes receivable as of March 31, 2024 and December 31, 2023 ($ in thousands): March 31, 2024 Maturity Date Stated Interest Rate Principal Amount Interest Receivable Fair Value Notes receivable, at fair value Convergent convertible note 12/2/2024 8% $ 816 $ - $ 816 Raefan Industries LLC 12/31/2024 8% $ 389 $ 751 $ 1,139 American Innovative Robotics 04/01/2027 8% $ 1,106 $ 22 $ 1,128 Notes receivable, at fair value - current portion $ 1,955 Notes receivable, at fair value - non-current portion $ 1,128 December 31, 2023 Maturity Date Stated Interest Rate Principal Amount Interest Receivable Fair Value Notes receivable, at fair value Convergent convertible note 12/2/2024 8% $ 1,006 $ 58 $ 1,064 Raefan Industries LLC 12/31/2024 8% $ 1,363 $ 751 $ 2,114 American Innovative Robotics 04/01/2027 8% $ 1,106 $ 22 $ 1,129 Notes receivable, at fair value - current portion $ 3,177 Notes receivable, at fair value - non-current portion $ 1,129 Convergent Therapeutics, Inc. The Company recorded principal repayment of approximately $0.3 million, interest income of approximately $63,000 and an unrealized gain on the note of approximately $60,000 on the Convergent Convertible Note for the three months ended March 31, 2024. Raefan Industries LLC The Company recorded a realized loss as a result of directly writing off approximately $1.0 million of principal, which the Company deemed uncollectible during the three months ended March 31, 2024. American Innovative Robotics, LLC The Company recorded interest income of approximately $22,000, and an unrealized loss on the note of approximately $1,000 on the Robotics Promissory Note for the three months ended March 31, 2024.

Fair Value of Financial Assets

Fair Value of Financial Assets and Liabilities	3 Months Ended
	Mar. 31, 2024
Fair Value of Financial Assets and Liabilities [Abstract]
Fair Value of Financial Assets and Liabilities	Note 7. Fair Value of Financial Assets and Liabilities Financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of inputs that may be used to measure fair value: Level 1 - quoted prices in active markets for identical assets or liabilities Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions) Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment. The following table presents the Company’s assets and liabilities that are measured at fair value as of March 31, 2024, and December 31, 2023 ($ in thousands): Fair value measured as of March 31, 2024 Total at December 31, Quoted prices in active markets Significant other observable inputs Significant unobservable inputs 2023 (Level 1) (Level 2) (Level 3) Assets Marketable securities: Equities $ 5,123 $ 5,123 $ - $ - Total marketable securities $ 5,123 $ 5,123 $ - $ - Notes receivable at fair value, current portion $ 1,955 $ - $ - $ 1,955 Notes receivable at fair value, non-current portion $ 1,128 $ - $ - $ 1,128 Fair value measured as of December 31, 2023 Total at December 31, Quoted prices in active markets Significant other observable inputs Significant unobservable inputs 2023 (Level 1) (Level 2) (Level 3) Assets Marketable securities: Equities $ 13,547 $ 13,547 $ - $ - Total marketable securities $ 13,547 $ 13,547 $ - $ - Notes receivable at fair value, current portion $ 3,177 $ - $ - $ 3,177 Notes receivable at fair value, non-current portion $ 1,129 $ - $ - $ 1,129 Level 3 Measurement The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands): Notes receivable at fair value, current portion at December 31, 2023 $ 3,177 Collection of principal outstanding (250 ) Realized and unrealized gain and loss on note receivable, net (915 ) Change in interest receivable (57 ) Notes receivable at fair value, current portion at March 31, 2024 $ 1,955 Notes receivable at fair value, non-current portion at December 31, 2023 $ 1,129 Unrealized loss on notes receivable (1 ) Notes receivable at fair value, non-current portion at March 31, 2024 $ 1,128 Notes Receivable at fair value As of March 31, 2024, the fair value of the notes receivable was measured taking into consideration cost basis, market participant inputs, market conditions, liquidity, operating results and other qualitative and quantitative factors. No material change was noted in the fair value of the notes receivable during the three months ended March 31, 2024.

Leases

Leases	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Leases	Note 8. Leases On December 1, 2021, the Company entered into a Lease Agreement (the “Company’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under the Company’s Lease, the Company rents a portion of the twenty-second floor at 725 Fifth Avenue, New York, New York (the “22 nd nd nd On September 23, 2022, Dominari Financial entered into a Lease Agreement (“Dominari Financial’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under Dominari Financial’s Lease, Dominari Financial rents a portion of a floor at 725 Fifth Avenue, New York, New York (the “Premises”). Dominari Financial currently uses the Premises to run its day-to-day operations. The initial term of Dominari Financial’s Lease is seven (7) years commencing on the date that possession of the Premises is delivered to Dominari Financial. Under Dominari Financial’s Lease, Dominari Financial is required to pay monthly rent equal to $49,368. Effective for the sixth and seventh years of Dominari Financial’s Lease, the rent shall increase to $51,868 per month. The Company took possession of the Premises in February 2023. The tables below represent the Company’s lease assets and liabilities as of March 31, 2024: March 31, Assets: Operating lease right-of-use-assets $ 3,242 Liabilities: Current Operating 419 Long-term Operating 2,929 $ 3,348 The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842: March 31, March 31, Weighted-average remaining lease term – operating leases (in years) 6.2 7.2 Weighted-average discount rate – operating leases 10.0 % 10.0 % During the three months ended March 31, 2024 and 2023, the Company recorded approximately $0.2 million, respectively, of lease expense to current period operations. Three Months Three Months March 31, March 31, Operating leases Operating lease cost $ 178 $ 134 Operating lease expense 178 134 Short-term lease rent expense 22 30 Net rent expense $ 200 $ 164 Supplemental cash flow information related to leases were as follows: Three Months Three Months March 31, March 31, Operating cash flows - operating leases $ 187 $ 34 Right-of-use assets obtained in exchange for operating lease liabilities $ - $ 2,796 As of March 31, 2024, future minimum payments during the next five years and thereafter are as follows: Operating Leases Remaining Period Ended December 31, 2024 560 Year Ended December 31, 2025 685 Year Ended December 31, 2026 685 Year Ended December 31, 2027 685 Year Ended December 31, 2028 766 Thereafter 1,160 Total 4,541 Less present value discount (1,193 ) Operating lease liabilities $ 3,348

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2024
Net Loss per Share [Abstract]
Net Loss per Share	Note 9. Net Loss per Share Basic loss per share of common stock is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding for the period. Diluted loss per common share is computed similar to basic loss per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock as of the first day of the period. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the three months ended March 31, 2024, and 2023 are as follows: As of March 31, 2024 2023 Convertible preferred stock 34 34 Warrants to purchase common stock 444,796 444,796 Restricted stock awards 136,309 - Options to purchase common stock 420,096 31,193 Total 1,001,235 476,023

Stockholders_ Equity and Conver

Stockholders’ Equity and Convertible Preferred Stock	3 Months Ended
	Mar. 31, 2024
Stockholders’ Equity and Convertible Preferred Stock [Abstract]
Stockholders’ Equity and Convertible Preferred Stock	Note 10. Stockholders’ Equity and Convertible Preferred Stock Common Stock As of March 31, 2024, there are 5,995,065 shares of common stock issued and 5,934,917 shares outstanding. Treasury Stock There are 60,148 shares of treasury stock as of March 31, 2024. Warrants A summary of warrant activity for the three months ended March 31, 2024, is presented below: Warrants Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life Outstanding as of December 31, 2023 444,796 $ 29.25 - 2.20 Granted - $ - - - Outstanding as of March 31, 2024 444,796 $ 29.25 - 1.95 Restricted Stock Awards A summary of restricted stock awards activity for the three months ended March 31, 2024, is presented below: Number of Restricted Stock Awards Weighted Average Grant Day Fair Value Nonvested at December 31, 2023 136,309 $ 2.26 Granted - $ - Vested - $ - Nonvested at March 31, 2024 136,309 $ 2.26 Stock-based compensation associated with the amortization of restricted stock awards expense was approximately $75,000 and $257 for the three months ended March 31, 2024, and 2023, respectively. All stock compensation was recorded as a component of general and administrative expenses. As of March 31, 2024, there is approximately $0.2 million unrecognized stock-based compensation expense related to restricted stock awards. Stock Options A summary of option activity under the Company’s stock option plan for the three months ended March 31, 2024, is presented below: Number of Shares Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2023 420,168 $ 5.80 $ - 9.3 Employee options expired (72 ) $ 6,410.74 - - Outstanding as of March 31, 2024 420,096 $ 4.71 $ - 9.0 Options vested and exercisable 108,666 $ 8.37 $ - 8.6 Stock-based compensation associated with the amortization of stock option expense was approximately $0.1 million and $5,000 for the three months ended March 31, 2024, and 2023, respectively. All stock compensation was recorded as a component of general and administrative expenses. Estimated future stock-based compensation expense relating to unvested stock options is approximately $0.4 million.

Revenue

Revenue	3 Months Ended
	Mar. 31, 2024
Revenue [Abstract]
Revenue	Note 11. Revenue The following table presents our total revenue disaggregated by revenue type for the three months ended March 31, 2024 and 2023 (in thousands): Three Months Ended 2024 2023 Underwriting $ 409 $ - Commissions 310 - Advisory fees 341 - Other 307 - Total $ 1,367 $ -

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 12. Commitments and Contingencies Legal Proceedings In March 2024, the Company received a notice of petition of a filed action seeking relief related to the hiring in March 2024 of new registered representatives from the representatives’ former employer. This notice was filed against the Company’s subsidiary, Dominari Securities. The Company does not agree with the plaintiff’s claims. While the Company intends to defend itself vigorously from this claim, it is unable to predict the outcome of such legal proceeding. Any potential loss as a result of this legal proceeding cannot be reasonably estimated. As a result, the Company has not recorded a loss contingency for the aforementioned claim. In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of the Company’s technology. Other than ordinary routine litigation incidental to the business, the Company is not aware of any material, active or pending legal proceedings brought against it.

Regulatory

Regulatory	3 Months Ended
	Mar. 31, 2024
Regulatory [Abstract]
Regulatory	Note 13. Regulatory Dominari Securities, the Company’s broker-dealer subsidiary, is registered with the SEC as an introducing broker-dealer and is a member of FINRA. The Company’s broker-dealer subsidiary is subject to SEC Uniform Net Capital Rule (Rule 15c3-1) which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. As such, the subsidiary is subject to the minimum net capital requirements promulgated by the SEC and has elected to calculate minimum capital requirements using the basic method permitted by Rule 15c3-1. As of March 31, 2024, Dominari Securities had net capital of approximately $13.4 million, which was approximately $13.3 million in excess of required minimum net capital of $0.1 million.

Related Party Transaction

Related Party Transaction	3 Months Ended
	Mar. 31, 2024
Related Party Transaction [Abstract]
Related Party Transaction	Note 14. Related Party Transaction In 2021, the Company engaged the services of Revere Securities, LLC (“Revere”) to strategically manage and build the Company’s investment processes. Kyle Wool, Board Member, was previously a member of the board of directors of Revere. The Company incurred fees of approximately $0 and $80,000 during the three months ending March 31, 2024 and 2023, respectively. These fees were included in general and administrative expenses in the unaudited condensed consolidated statements of operations.

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
Segment Reporting	Note 15. Segment Reporting The Company operates in two reportable business segments: (1) Dominari Financial and (2) Legacy AIkido. The Dominari Financial reportable business segment represents the Company’s broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. Prior to the FPS Acquisition, the Company operated as a single operating segment comprised of Legacy AIkido. The chief operating decision-maker (“CODM”) has access to and regularly reviews internal financial reporting for each business and uses that information to make operational decisions and allocate resources. Accounting policies applied by the reportable segments are the same as those used by the Company and described in the “ Summary of Significant Accounting Policies. The measures of segment profitability that are most relied upon by the CODM are gross revenue and net loss, as presented within the table below and reconciled to the statement of operations. Three Months Ended Dominari Legacy Consolidated Revenue $ 1,367 $ - $ 1,367 Operating Costs General and administrative 2,712 1,460 $ 4,172 Loss from operations $ (1,345 ) $ (1,460 ) $ (2,805 ) Other income (expenses) Other income - - - Interest income 137 27 164 Gain on marketable securities - 574 574 Realized and unrealized gain and loss on notes receivable, net - (915 ) (915 ) Change in fair value of long-term equity investments (2,459 ) (2,459 ) Total other income (expenses) $ 137 $ (2,773 ) $ (2,636 ) Net loss $ (1,208 ) $ (4,233 ) $ (5,441 )

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2024
Income Taxes [Abstract]
Income Taxes	Note 16. Income Taxes The Company recorded no As of March 31, 2024, and December 31, 2023, the Company provided a full valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (5,441)	$ (3,762)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2024
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed consolidated balance sheet as of March 31, 2024, condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023, condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2024 and 2023, and the condensed consolidated statements of cash flows for the three months ended March 31, 2024 and 2023 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three months ended March 31, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024 or for any future interim period. The condensed consolidated balance sheet as of December 31, 2023 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2023. The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.
Deposits with clearing broker	Deposits with clearing broker Deposits with Dominari Securities’ clearing broker consisted of approximately $14.1 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of March 31, 2024.
Leases	Leases The Company accounts for its leases under ASC 842, Leases Leases
Revenue	Revenue The Company recognizes revenue under ASC 606 - Revenue from Contracts with Customers . The following provides detailed information on the recognition of the Company’s revenue from contracts with customers: ● Underwriting services include underwriting and placement agent services in both the equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenue are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the unaudited condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income. ● Commissions are earned by executing transactions for clients primarily in equity, equity-related, and debt products. Commission revenue associated with trade execution are recognized at a point in time on trade-date. Commissions revenue are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date. ● Account advisory fees are earned in connection with investment advisory services. Account advisory fees are recognized over time using the time elapsed method as the Company determined that the customer simultaneously receives and consumes the benefits of investment advisory services as they are provided. Account advisory fees are generally paid in advance of a specified service period (e.g. quarterly) and are initially deferred within in our Condensed Consolidated Balance Sheet. ● Other revenue includes placement agent services in the equity capital markets for privately held companies distributing private equity. Placement agent revenue are recognized at a point in time on trade-date, as the client obtains the control and benefit of the membership interest offering at that point.
Long-term equity investments	Long-term equity investments The Company accounts for long-term equity investments under Accounting Standards Codification (“ASC”) 321 “Investments—Equity Securities” (“ASC 321”). In accordance with ASC 321, equity securities with readily determinable fair values are accounted for at fair value based on quoted market prices. Equity securities without readily determinable fair values are accounted for either at fair value or using the measurement alternative. Under the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the Company.
Recently adopted accounting standards	Recently adopted accounting standards In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions In March 2023, the FASB issued ASU 2023-01, Leases
Effect of new accounting pronouncements to be adopted in future periods	Effect of new accounting pronouncements to be adopted in future periods The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.

Marketable Securities (Tables)

Marketable Securities (Tables)	3 Months Ended
	Mar. 31, 2024
Marketable Securities [Abstract]
Schedule of Marketable Securities	The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three months ended March 31, 2024 and 2023, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands): Three Months Ended 2024 2023 Realized loss $ (93 ) $ (56 ) Unrealized gain (loss) 473 (130 ) Dividend income 193 121 Total $ 574 $ (65 )

Long-Term Equity Investments (T

Long-Term Equity Investments (Tables)	3 Months Ended
	Mar. 31, 2024
Long-Term Equity Investments [Abstract]
Schedule of Long-Term Investments	The following table presents the Company’s long-term investments as of March 31, 2024, and December 31, 2023 ($ in thousands): Cost Basis March 31, December 31, Investment in Kerna Health Inc $ 2,140 $ 4,940 $ 4,940 Investment in Kaya Now 1,500 - - Investment in Tevva Motors 1,972 2,794 2,794 Investment in ASP Isotopes 1,300 - - Investment in Unusual Machines 1,075 813 1,033 Investment in Qxpress* 1,000 1,000 1,000 Investment in Masterclass* 170 170 170 Investment in Kraken* 597 597 597 Investment in Epic Games* 3,500 2,626 3,500 Investment in Tesspay** 1,240 2,981 2,679 Investment in SpaceX* 3,500 3,500 4,867 Investment in Databricks* 1,200 842 842 Investment in Discord* 476 476 476 Investment in Thrasio* 300 - 300 Investment in Automation Anywhere* 476 476 476 Investment in Anduril* 476 476 476 Total $ 20,922 $ 21,691 $ 24,150 * Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly. ** Investments made in these companies are through both an SPV and direct investments.

Notes Receivable (Tables)

Notes Receivable (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Receivable [Abstract]
Schedule of Notes Receivable	The following table presents the Company’s notes receivable as of March 31, 2024 and December 31, 2023 ($ in thousands): Maturity Date Stated Interest Rate Principal Amount Interest Receivable Fair Value Notes receivable, at fair value Convergent convertible note 12/2/2024 8% $ 816 $ - $ 816 Raefan Industries LLC 12/31/2024 8% $ 389 $ 751 $ 1,139 American Innovative Robotics 04/01/2027 8% $ 1,106 $ 22 $ 1,128 Notes receivable, at fair value - current portion $ 1,955 Notes receivable, at fair value - non-current portion $ 1,128 Maturity Date Stated Interest Rate Principal Amount Interest Receivable Fair Value Notes receivable, at fair value Convergent convertible note 12/2/2024 8% $ 1,006 $ 58 $ 1,064 Raefan Industries LLC 12/31/2024 8% $ 1,363 $ 751 $ 2,114 American Innovative Robotics 04/01/2027 8% $ 1,106 $ 22 $ 1,129 Notes receivable, at fair value - current portion $ 3,177 Notes receivable, at fair value - non-current portion $ 1,129

Fair Value of Financial Asset_2

Fair Value of Financial Assets and Liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value of Financial Assets and Liabilities [Abstract]
Schedule of Assets and Liabilities are Measured at Fair Value	The following table presents the Company’s assets and liabilities that are measured at fair value as of March 31, 2024, and December 31, 2023 ($ in thousands): Fair value measured as of March 31, 2024 Total at December 31, Quoted prices in active markets Significant other observable inputs Significant unobservable inputs 2023 (Level 1) (Level 2) (Level 3) Assets Marketable securities: Equities $ 5,123 $ 5,123 $ - $ - Total marketable securities $ 5,123 $ 5,123 $ - $ - Notes receivable at fair value, current portion $ 1,955 $ - $ - $ 1,955 Notes receivable at fair value, non-current portion $ 1,128 $ - $ - $ 1,128 Fair value measured as of December 31, 2023 Total at December 31, Quoted prices in active markets Significant other observable inputs Significant unobservable inputs 2023 (Level 1) (Level 2) (Level 3) Assets Marketable securities: Equities $ 13,547 $ 13,547 $ - $ - Total marketable securities $ 13,547 $ 13,547 $ - $ - Notes receivable at fair value, current portion $ 3,177 $ - $ - $ 3,177 Notes receivable at fair value, non-current portion $ 1,129 $ - $ - $ 1,129
Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands): Notes receivable at fair value, current portion at December 31, 2023 $ 3,177 Collection of principal outstanding (250 ) Realized and unrealized gain and loss on note receivable, net (915 ) Change in interest receivable (57 ) Notes receivable at fair value, current portion at March 31, 2024 $ 1,955 Notes receivable at fair value, non-current portion at December 31, 2023 $ 1,129 Unrealized loss on notes receivable (1 ) Notes receivable at fair value, non-current portion at March 31, 2024 $ 1,128

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Schedule of Lease Assets and Liabilities	The tables below represent the Company’s lease assets and liabilities as of March 31, 2024: March 31, Assets: Operating lease right-of-use-assets $ 3,242 Liabilities: Current Operating 419 Long-term Operating 2,929 $ 3,348
Schedule of Summarize Quantitative Information about the Company’s Operating Leases	The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842: March 31, March 31, Weighted-average remaining lease term – operating leases (in years) 6.2 7.2 Weighted-average discount rate – operating leases 10.0 % 10.0 %
Schedule of Lease Expense to Current Period Operations	During the three months ended March 31, 2024 and 2023, the Company recorded approximately $0.2 million, respectively, of lease expense to current period operations. Three Months Three Months March 31, March 31, Operating leases Operating lease cost $ 178 $ 134 Operating lease expense 178 134 Short-term lease rent expense 22 30 Net rent expense $ 200 $ 164
Schedule of Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases were as follows: Three Months Three Months March 31, March 31, Operating cash flows - operating leases $ 187 $ 34 Right-of-use assets obtained in exchange for operating lease liabilities $ - $ 2,796
Schedule of Future Minimum Payments	As of March 31, 2024, future minimum payments during the next five years and thereafter are as follows: Operating Leases Remaining Period Ended December 31, 2024 560 Year Ended December 31, 2025 685 Year Ended December 31, 2026 685 Year Ended December 31, 2027 685 Year Ended December 31, 2028 766 Thereafter 1,160 Total 4,541 Less present value discount (1,193 ) Operating lease liabilities $ 3,348

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2024
Net Loss per Share [Abstract]
Schedule of Computation of Diluted Loss Per Share	Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the three months ended March 31, 2024, and 2023 are as follows: As of March 31, 2024 2023 Convertible preferred stock 34 34 Warrants to purchase common stock 444,796 444,796 Restricted stock awards 136,309 - Options to purchase common stock 420,096 31,193 Total 1,001,235 476,023

Stockholders_ Equity and Conv_2

Stockholders’ Equity and Convertible Preferred Stock (Tables)	3 Months Ended
	Mar. 31, 2024
Stockholders’ Equity and Convertible Preferred Stock [Abstract]
Schedule of Warrant Activity	A summary of warrant activity for the three months ended March 31, 2024, is presented below: Warrants Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life Outstanding as of December 31, 2023 444,796 $ 29.25 - 2.20 Granted - $ - - - Outstanding as of March 31, 2024 444,796 $ 29.25 - 1.95
Schedule of Restricted Stock Awards Activity	A summary of restricted stock awards activity for the three months ended March 31, 2024, is presented below: Number of Restricted Stock Awards Weighted Average Grant Day Fair Value Nonvested at December 31, 2023 136,309 $ 2.26 Granted - $ - Vested - $ - Nonvested at March 31, 2024 136,309 $ 2.26
Schedule of Stock Option Activity	A summary of option activity under the Company’s stock option plan for the three months ended March 31, 2024, is presented below: Number of Shares Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2023 420,168 $ 5.80 $ - 9.3 Employee options expired (72 ) $ 6,410.74 - - Outstanding as of March 31, 2024 420,096 $ 4.71 $ - 9.0 Options vested and exercisable 108,666 $ 8.37 $ - 8.6

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2024
Revenue [Abstract]
Schedule of Total Revenues Disaggregated by Revenue Type	The following table presents our total revenue disaggregated by revenue type for the three months ended March 31, 2024 and 2023 (in thousands): Three Months Ended 2024 2023 Underwriting $ 409 $ - Commissions 310 - Advisory fees 341 - Other 307 - Total $ 1,367 $ -

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenues and Net Loss	The measures of segment profitability that are most relied upon by the CODM are gross revenue and net loss, as presented within the table below and reconciled to the statement of operations. Three Months Ended Dominari Legacy Consolidated Revenue $ 1,367 $ - $ 1,367 Operating Costs General and administrative 2,712 1,460 $ 4,172 Loss from operations $ (1,345 ) $ (1,460 ) $ (2,805 ) Other income (expenses) Other income - - - Interest income 137 27 164 Gain on marketable securities - 574 574 Realized and unrealized gain and loss on notes receivable, net - (915 ) (915 ) Change in fair value of long-term equity investments (2,459 ) (2,459 ) Total other income (expenses) $ 137 $ (2,773 ) $ (2,636 ) Net loss $ (1,208 ) $ (4,233 ) $ (5,441 )

Organization and Description _2

Organization and Description of Business and Recent Developments (Details) - USD ($) $ in Millions		3 Months Ended
	Oct. 04, 2022	Mar. 31, 2024	Sep. 09, 2022
Organization and Description of Business and Recent Developments [Line Items]
Seller paid (in Dollars)	$ 2
Additional seller paid (in Dollars)		$ 1.4
FPS Purchase Agreement [Member]
Organization and Description of Business and Recent Developments [Line Items]
Membership interests rate			100%
FPS Purchase Agreement [Member]
Organization and Description of Business and Recent Developments [Line Items]
Membership interests rate	20%	80%

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details) $ in Millions	Mar. 31, 2024 USD ($)
Summary of Significant Accounting Policies [Abstract]
Money market funds	$ 14.1

Marketable Securities (Details)

Marketable Securities (Details) - Schedule of Marketable Securities - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule of Marketable Securities [Abstract]
Realized loss	$ (93)	$ (56)
Unrealized gain (loss)	473	(130)
Dividend income	193	121
Total	$ 574	$ (65)

Long-Term Equity Investments (D

Long-Term Equity Investments (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended
	Apr. 30, 2024	Feb. 14, 2024
Long-Term Equity Investments (Details) [Line Items]
Public offering price		$ 4
Subsequent Event [Member]
Long-Term Equity Investments (Details) [Line Items]
Redemption amount	$ 3.5

Long-Term Equity Investments _2

Long-Term Equity Investments (Details) - Schedule of Long-Term Investments - USD ($) $ in Thousands		Mar. 31, 2024	Dec. 31, 2023
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis		$ 20,922
Long-term investments, Total		21,691	$ 24,150
Investment In Kerna Health Inc [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis		2,140
Long-term investments, Total		4,940	4,940
Investment in Kaya Now [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis		1,500
Long-term investments, Total
Investment in Tevva Motors [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis		1,972
Long-term investments, Total		2,794	2,794
Investment in ASP Isotopes [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis		1,300
Long-term investments, Total
Investment in Unusual Machines [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis		1,075
Long-term investments, Total		813	1,033
Investment in Qxpress [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	[1]	1,000
Long-term investments, Total	[1]	1,000	1,000
Investment in Masterclass [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	[1]	170
Long-term investments, Total	[1]	170	170
Investment in Kraken [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	[1]	597
Long-term investments, Total	[1]	597	597
Investment in Epic Games [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	[1]	3,500
Long-term investments, Total	[1]	2,626	3,500
Investment in Tesspay [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	[2]	1,240
Long-term investments, Total	[2]	2,981	2,679
Investment in SpaceX [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	[1]	3,500
Long-term investments, Total	[1]	3,500	4,867
Investment in Databricks [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	[1]	1,200
Long-term investments, Total	[1]	842	842
Investment in Discord [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	[1]	476
Long-term investments, Total	[1]	476	476
Investment in Thrasio [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	[1]	300
Long-term investments, Total	[1]		300
Investment in Automation Anywhere [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	[1]	476
Long-term investments, Total	[1]	476	476
Investment in Anduril [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis		476
Long-term investments, Total		$ 476	$ 476
[1] Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly.

Notes Receivable (Details)

Notes Receivable (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($)
Notes Receivable [Line Items]
Interest income	$ 63,000
Convergent Therapeutics, Inc. [Member]
Notes Receivable [Line Items]
Principal repayment	300
Unrealized gain	60,000
Raefan Industries LLC [Member]
Notes Receivable [Line Items]
Unrealized loss	1,000
American Innovative Robotics, LLC [Member]
Notes Receivable [Line Items]
Interest income	22,000
Unrealized loss	$ 1,000

Notes Receivable (Details) - Sc

Notes Receivable (Details) - Schedule of Notes Receivable - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Convergent convertible note - current [Member]
Notes receivable, at fair value
Maturity Date	Dec. 02, 2024
Stated Interest Rate	8%
Principal Amount	$ 816
Interest Receivable
Fair Value	$ 816
Raefan Industries LLC [Member]
Notes receivable, at fair value
Maturity Date	Dec. 31, 2024	Dec. 31, 2024
Stated Interest Rate	8%	8%
Principal Amount	$ 389	$ 1,363
Interest Receivable	751	751
Fair Value	$ 1,139	$ 2,114
American Innovative Robotics [Member]
Notes receivable, at fair value
Maturity Date	Apr. 01, 2027	Apr. 01, 2027
Stated Interest Rate	8%	8%
Principal Amount	$ 1,106	$ 1,106
Interest Receivable	22	22
Fair Value	1,128	1,129
Notes receivable, at fair value - current portion [Member]
Notes receivable, at fair value
Fair Value	1,955	3,177
Notes receivable, at fair value - non-current portion [Member]
Notes receivable, at fair value
Fair Value	$ 1,128	$ 1,129
Convergent convertible note - current [Member]
Notes receivable, at fair value
Maturity Date		Dec. 02, 2024
Stated Interest Rate		8%
Principal Amount		$ 1,006
Interest Receivable		58
Fair Value		$ 1,064

Fair Value of Financial Asset_3

Fair Value of Financial Assets and Liabilities (Details) - Schedule of Assets and Liabilities are Measured at Fair Value - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Marketable securities:
Equities	$ 5,123	$ 13,547
Total marketable securities	5,123	13,547
Notes receivable at fair value, current portion	1,955	3,177
Notes receivable at fair value,non-current portion	1,128	1,129
Short-term investment		1,128
Quoted prices in active markets (Level 1) [Member]
Marketable securities:
Equities	5,123	13,547
Total marketable securities	5,123	13,547
Notes receivable at fair value, current portion
Notes receivable at fair value,non-current portion
Short-term investment
Significant other observable inputs (Level 2) [Member]
Marketable securities:
Equities
Total marketable securities
Notes receivable at fair value, current portion
Notes receivable at fair value,non-current portion
Short-term investment
Significant unobservable inputs (Level 3) [Member]
Marketable securities:
Equities
Total marketable securities
Notes receivable at fair value, current portion	1,955	3,177
Notes receivable at fair value,non-current portion	$ 1,128	1,129
Short-term investment		$ 1,128

Fair Value of Financial Asset_4

Fair Value of Financial Assets and Liabilities (Details) - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis - Level 3 [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($)
Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis [Line Items]
Notes receivable at fair value, current portion, Balance beginning	$ 3,177
Notes receivable at fair value, current portion at Balance ending	1,955
Notes receivable at fair value, non-current portion Balance beginning	1,129
Notes receivable at fair value, non-current portion Balance ending	1,128
Collection of principal outstanding	(250)
Realized and unrealized gain and loss on note receivable, net	(915)
Change in interest receivable	(57)
Unrealized loss on notes receivable	$ (1)

Leases (Details)

Leases (Details) - USD ($) $ in Thousands			3 Months Ended
	Jan. 11, 2023	Sep. 23, 2022	Mar. 31, 2024	Mar. 31, 2023	Jul. 11, 2022
Leases [Abstract]
Lease term		7 years			7 years
Rent expenses	$ 12,874
Increase rent amount		$ 51,868	$ 13,502
Rent payment		$ 49,368
Lease expenses			$ 200	$ 200
Future minimum payments lease term			5 years

Leases (Details) - Schedule of

Leases (Details) - Schedule of Lease Assets and Liabilities - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Assets:
Operating lease right-of-use-assets	$ 3,242	$ 3,335
Liabilities:
Operating current	419	421
Long-term
Operating non-current	2,929	$ 3,028
Total	$ 3,348

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Summarize Quantitative Information about the Company’s Operating Leases	Mar. 31, 2024	Mar. 31, 2023
Schedule of Summarize Quantitative Information about the Company’s Operating Leases [Line Items]
Weighted-average remaining lease term – operating leases (in years)	6 years 2 months 12 days	7 years 2 months 12 days
Weighted-average discount rate – operating leases	10%	10%

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of Lease Expense - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating leases
Operating lease cost	$ 178	$ 134
Operating lease expense	178	134
Short-term lease rent expense	22	30
Net rent expense	$ 200	$ 164

Leases (Details) - Schedule o_4

Leases (Details) - Schedule of Supplemental Cash Flow Information Related to Leases - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule of Supplemental Cash Flow Information Related to Leases [Abstract]
Operating cash flows - operating leases	$ 187	$ 34
Right-of-use assets obtained in exchange for operating lease liabilities		$ 2,796

Leases (Details) - Schedule o_5

Leases (Details) - Schedule of Future Minimum Payments $ in Thousands	Mar. 31, 2024 USD ($)
Schedule of Future Minimum Payments [Abstract]
Remaining Period Ended December 31, 2024	$ 560
Year Ended December 31, 2025	685
Year Ended December 31, 2026	685
Year Ended December 31, 2027	685
Year Ended December 31, 2028	766
Thereafter	1,160
Total	4,541
Less present value discount	(1,193)
Operating lease liabilities	$ 3,348

Net Loss Per Share (Details) -

Net Loss Per Share (Details) - Schedule of Computation of Diluted Loss Per Share - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule of Computation of Diluted Loss Per Share [Abstract]
Total diluted loss per share	1,001,235	476,023
Convertible preferred stock [Member]
Schedule of Computation of Diluted Loss Per Share [Abstract]
Total diluted loss per share	34	34
Warrants to purchase common stock [Member]
Schedule of Computation of Diluted Loss Per Share [Abstract]
Total diluted loss per share	444,796	444,796
Restricted stock awards [Member]
Schedule of Computation of Diluted Loss Per Share [Abstract]
Total diluted loss per share	136,309
Options to purchase common stock [Member]
Schedule of Computation of Diluted Loss Per Share [Abstract]
Total diluted loss per share	420,096	31,193

Stockholders_ Equity and Conv_3

Stockholders’ Equity and Convertible Preferred Stock (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Stockholders’ Equity and Convertible Preferred Stock [Line Items]
Common stock, shares issued (in Shares)	5,995,065		5,995,065
Common stock, shares outstanding (in Shares)	5,934,917		5,934,917
Treasury stock shares (in Shares)	60,148		60,148
Share based compensation expense	$ 100	$ 5,000
unrecognized stock-based compensation expense	200
Estimated future stock-based compensation expense	400
Restricted Stock Awards [Member]
Stockholders’ Equity and Convertible Preferred Stock [Line Items]
Share based compensation expense	$ 75,000	$ 257
Common Stock [Member]
Stockholders’ Equity and Convertible Preferred Stock [Line Items]
Common stock, shares issued (in Shares)	5,995,065
Common stock, shares outstanding (in Shares)	5,934,917

Stockholders_ Equity and Conv_4

Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Warrant Activity - Warrant [Member] - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Schedule of Warrant Activity [Line Items]
Number of shares, ending balance	444,796	444,796
Weighted Average per share, ending balance	$ 29.25	$ 29.25
Outstanding ending balance, Total Intrinsic Value
Outstanding ending balance, Weighted Average Remaining Contractual Life	1 year 11 months 12 days	2 years 2 months 12 days
Granted, Warrants
Granted, Weighted Average Exercise Price
Granted, Total Intrinsic Value
Granted, Weighted Average Remaining Contractual Life

Stockholders_ Equity and Conv_5

Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Schedule of Restricted Stock Awards Activity [Abstract]
Number of shares, beginning balance | shares	136,309
Weighted Average per share, beginning balance | $ / shares	$ 2.26
Number of shares, ending balance | shares	136,309
Weighted Average per share, ending balance | $ / shares	$ 2.26
Number of Restricted Stock Awards, Granted | shares
Weighted Average Grant Day Fair Value, Granted | $ / shares
Number of Restricted Stock Awards, Vested | shares
Weighted Average Grant Day Fair Value, Vested | $ / shares

Stockholders_ Equity and Conv_6

Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Activity - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Schedule of Stock Option Activity [Abstract]
Outstanding ending balance, Number of Shares	420,096	420,168
Outstanding ending balance, Weighted Average Exercise Price	$ 4.71	$ 5.8
Outstanding ending balance, Intrinsic Value
Outstanding ending balance, Weighted Average Remaining Contractual Life	9 years	9 years 3 months 18 days
Number of Shares, Options vested and exercisable	108,666
Weighted Average Exercise Price, Options vested and exercisable	$ 8.37
Total Intrinsic Value, Options vested and exercisable
Weighted Average Remaining Contractual Life (in years), Options vested and exercisable	8 years 7 months 6 days
Employee options expired, Number of Shares	(72)
Employee options expired, Weighted Average Exercise Price	$ 6,410.74
Employee options expired, Intrinsic Value
Employee options expired , Weighted Average Remaining Contractual Life

Revenue (Details) - Schedule of

Revenue (Details) - Schedule of Total Revenues Disaggregated by Revenue Type - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule of Total Revenues Disaggregated by Revenue Type [Abstract]
Underwriting	$ 409
Commissions	310
Advisory fees	341
Other	307
Total	$ 1,367

Regulatory (Details)

Regulatory (Details) $ in Millions	Mar. 31, 2024 USD ($)
Regulatory [Line Items]
Net capital amount	$ 0.1
Excess amount	13.3
Dominari Securities [Member]
Regulatory [Line Items]
Net capital amount	$ 13.4

Related Party Transaction (Deta

Related Party Transaction (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Related Party Transaction [Abstract]
Incurred fees	$ 0	$ 80,000

Segment Reporting (Details)

Segment Reporting (Details)	3 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
Reportable segments	2

Segment Reporting (Details) - S

Segment Reporting (Details) - Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenues and Net Loss $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($)
Dominari Financial [Member]
Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenues and Net Loss [Line Items]
Revenue	$ 1,367
Operating Costs
General and administrative	2,712
Loss from operations	(1,345)
Other income (expenses)
Other income
Interest income	137
Gain on marketable securities
Realized and unrealized gain and loss on notes receivable, net
Total other income (expenses)	137
Net loss	(1,208)
Legacy AIkido [Member]
Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenues and Net Loss [Line Items]
Revenue
Operating Costs
General and administrative	1,460
Loss from operations	(1,460)
Other income (expenses)
Other income
Interest income	27
Gain on marketable securities	574
Realized and unrealized gain and loss on notes receivable, net	(915)
Change in fair value of long-term equity investments	(2,459)
Total other income (expenses)	(2,773)
Net loss	(4,233)
Consolidated [Member]
Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenues and Net Loss [Line Items]
Revenue	1,367
Operating Costs
General and administrative	4,172
Loss from operations	(2,805)
Other income (expenses)
Other income
Interest income	164
Gain on marketable securities	574
Realized and unrealized gain and loss on notes receivable, net	(915)
Change in fair value of long-term equity investments	(2,459)
Total other income (expenses)	(2,636)
Net loss	$ (5,441)

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Taxes [Abstract]
Income tax expense